REX Peptide ETF (NASDAQ:PEPT – Get Free Report) was the recipient of a large growth in short interest in October. As of October 30th, there was short interest totaling 8,874 shares, a growth of 3,844.0% from the October 15th total of 225 shares. Currently, 7.4% of the company’s stock are sold short. Based on an average daily volume of 7,975 shares, the short-interest ratio is currently 1.1 days.
REX Peptide ETF Trading Down 0.4%
NASDAQ PEPT traded down $0.11 on Tuesday, reaching $27.71. The company had a trading volume of 5,029 shares, compared to its average volume of 7,117. REX Peptide ETF has a 52-week low of $25.06 and a 52-week high of $28.14. The firm has a market capitalization of $3.33 million and a P/E ratio of 6,423.27.
REX Peptide ETF (NASDAQ: PEPT) is an exchange-traded fund designed to provide targeted exposure to companies involved in the development, production, and commercialization of peptide-based medicines and related technologies. Rather than operating as a traditional company, the fund holds a portfolio of businesses participating in the broader peptide therapeutics industry. The fund’s investment focus may include pharmaceutical and biotechnology companies developing peptide treatments, as well as businesses supporting peptide research, drug discovery, manufacturing, delivery systems, and related healthcare applications.
Featured Stories
- Five stocks we like better than REX Peptide ETF
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for REX Peptide ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REX Peptide ETF and related companies with MarketBeat.com's FREE daily email newsletter.
